Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
In a U.S. Phase II trial in 34 evaluable patients given once- or twice-weekly Velcade plus Rituxan rituximab, response rates were 41% and 35%, respectively. Complete or unconfirmed complete responses...
